Form 4: Inmune Bio Director Granted 150,000 Stock Options

Inmune Bio, Inc. Director Timothy J. Schroeder was granted 150,000 stock options with an exercise price of $1.48, vesting over three years.

Summary

• Timothy J. Schroeder, a Director of Inmune Bio, Inc. (INMB), was granted 150,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options was December 1, 2025.
• The options will vest pro rata on a monthly basis over three years (1/36 per month), becoming fully vested on the three-year anniversary of the grant date.
• The expiration date for these options is November 23, 2035.
• The grant was made pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and incentivizing long-term performance. It's a standard compensation practice.

Positives

• The grant of stock options to a director aligns management's interests with shareholders, incentivizing long-term performance.
• The three-year vesting schedule encourages sustained commitment and performance from the director.

Future Outlook

The vesting schedule over three years suggests an expectation of continued service and performance from the director, aligning their incentives with the company's long-term success.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry to attract and retain talent, aligning their interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of executive and director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The three-year vesting schedule is typical for long-term incentive plans, comparable to practices at companies like Biogen (BIIB) or Amgen (AMGN) for similar roles, though the specific number of options and exercise price would vary based on company size, stock price, and individual contribution.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to incentivized management, balanced against potential future dilution if options are exercised.
• Employees: No direct impact mentioned, but this is part of a broader compensation strategy for key personnel.

Next Steps

• The options will vest monthly over the next three years, with full vesting on December 1, 2028.
• The director may choose to exercise these options at any point after they vest and before their expiration date of November 23, 2035.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. While it aligns the director's interests with long-term shareholder value, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Inmune Bio, INMB, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Timothy J. Schroeder